Role of Gut Microbiome in Cancer Treatment

Abstract

The gut microbiota influences the effectiveness and side effects of cancer treatments, particularly immunotherapy and associated immune-related complications. This important involvement of the microbiome is supported by the patients receiving antibiotics responding poorly to immunotherapy. Relatively few research has examined the underlying processes, and until recently, data regarding the detection of the microbial organisms that trigger these effects were inconsistent. Since then, a deeper comprehension of the processes of action and taxonomic classification of the relevant species has been attained. It's been demonstrated that certain bacterial species can enhance the body’s reaction to immune checkpoint inhibitors through the release of distinct metabolites or products. Nonetheless, in certain patients who are not responding, Gram-negative bacteria may have a dominating suppressive impact. Patients' propensity to react to immunotherapy can be somewhat accurately predicted by machine learning techniques based on their microbiome makeup. Consequently, there has been an increase in interest in modifying the microbiome makeup to enhance patient reaction to medication. Clinical proof-of-concept studies demonstrate that dietary modifications or fecal microbiota transplantation (FMT) might be used therapeutically to increase the efficacy of immunotherapy in cancer patients. Current developments and new approaches for microbiota-based cancer treatments have been emphasized. In conclusion, preclinical research on animals and human clinical trials has made tremendous progress in our understanding of the function of the gut microbiome in health and illness. These investigations have shed light on the effects of food, FMT, probiotics, prebiotics, and microbiome-disease connections. However, there are still a lot of issues and restrictions that must be resolved before this research can be used in real-world clinical settings.

Graphical Abstract

Introduction

The gut microbiome, composed of trillions of microorganisms residing in the human digestive tract, plays a crucial role in maintaining overall health and influencing various physiological processes. Recent research has provided compelling evidence of the gut microbiome's involvement in cancer development and progression. This article explores the intricate relationship between the gut microbiome and cancer, with a focus on specific cancer types, potential mechanisms, and therapeutic implications [1].

Cancer is a complex and multifaceted disease, and emerging research suggests that the gut microbiome, the community of microorganisms residing in the gastrointestinal tract, has a significant impact on cancer development. The gut microbiome is known to affect various aspects of human health, including metabolism, immune function, and inflammation. The interplay between the gut microbiome and cancer is a burgeoning field of study that promises novel insights into the prevention, diagnosis, and treatment of various cancer types [2].

Cancer remains one of the most challenging global health issues, and the search for novel approaches to its prevention and treatment is ongoing. Recent advancements in the field of oncology have shed light on the significant influence of the gut microbiome on cancer development and progression. In this comprehensive review, we will explore the intricate relationship between the gut microbiome and cancer, focusing on the understanding of the gut microbiome, its impact on cancer development, and variations in the gut microbiome across different cancer types.

Gut microbiome and Cancer

Understanding the Gut Microbiome

The gut microbiome, a complex ecosystem of microorganisms inhabiting the human gastrointestinal tract, plays a pivotal role in maintaining overall health. Comprising bacteria, viruses, fungi, archaea, and other microorganisms, this diverse community coexists with the human host, influencing various physiological processes. Several factors influence the composition of the gut microbiome, including genetics, diet, age, and environmental exposures [3].

Recent advances in sequencing technologies have enabled the characterization of the gut microbiome with unprecedented precision. The gut microbiome is primarily composed of two dominant phyla: Firmicutes and Bacteroidetes, with a smaller representation of Proteobacteria, Actinobacteria, and others. The diversity and stability of this microbiome are crucial for its proper functioning, as imbalances can lead to various health issues [4].

Gut Microbiome and Cancer Development

Over the past decade, accumulating evidence has demonstrated the profound impact of the gut microbiome on cancer initiation and progression. The gut microbiome's influence on cancer is a multifaceted process, encompassing various mechanisms.

Inflammation and Carcinogenesis

Inflammation is a well-established driver of cancer, and the gut microbiome can contribute to inflammation through several pathways. Dysbiosis, an imbalance in the gut microbial community, can lead to chronic low-grade inflammation in the gut, which has been linked to cancer development [5]. Inflammatory responses in the gut can damage DNA, leading to mutations that increase cancer risk.

Metabolite Production

Microbes within the gut microbiome metabolize dietary components, producing various metabolites, some of which can influence cancer development. For example, the fermentation of dietary fiber by certain gut bacteria produces short-chain fatty acids (SCFAs), including butyrate, acetate, and propionate. SCFAs have been shown to have both pro-carcinogenic and anti-carcinogenic effects, depending on the specific SCFA, context, and cancer type [6]. They can affect apoptosis, cell differentiation, and cell proliferation, thereby influencing cancer development.

Immune System Modulation

The gut microbiome exerts a substantial impact on the host's immune system. Microbial components, such as lipopolysaccharides (LPS), can trigger immune responses. Alterations in the gut microbiome composition can influence immune system activity, potentially promoting or inhibiting cancer progression. For instance, specific bacteria can stimulate the recruitment of immune cells to tumor sites, enhancing the immune response against cancer cells [7]. Conversely, some gut microbes can induce immune tolerance, allowing tumors to evade immune surveillance.

Gut Microbiome Variations in Different Types of Cancer

The gut microbiome's role in cancer is not limited to a single malignancy but extends to various cancer types, each exhibiting unique relationships with specific microbial signatures (Fig. 1).

Fig. 1.

Variations in gut microbiome different types of cancer

Colorectal Cancer

Colorectal cancer (CRC) is among the most well-studied malignancies concerning the gut microbiome. Certain bacterial species, such as Fusobacterium nucleatum and Bacteroides fragilis, have been linked to an increased risk of CRC [8, 9]. These bacteria can promote inflammation and DNA damage, contributing to carcinogenesis. Conversely, some gut microbes, such as certain strains of Escherichia coli and Clostridium, can exert anti-tumor effects by producing metabolites that inhibit cancer cell growth [10, 11].

Breast Cancer

While less explored than CRC, the gut microbiome's role in breast cancer is gaining attention. Research suggests that the gut microbiome may influence breast cancer risk and progression through hormonal and inflammatory pathways [12]. For instance, gut microbes can metabolize estrogen, potentially affecting estrogen levels and breast cancer risk.

Pancreatic Cancer

Pancreatic cancer is characterized by a highly desmoplastic microenvironment. Recent studies have highlighted the role of the gut microbiome in modulating the pancreatic tumor microenvironment and response to treatment [13]. Specific bacteria have been associated with a worse prognosis and resistance to therapy in pancreatic cancer.

Liver Cancer

Hepatocellular carcinoma (HCC), the most common form of liver cancer, is also influenced by the gut microbiome. Recent research indicates that gut microbes can impact liver health and the development of HCC through the gut-liver axis [14]. Dysbiosis can lead to chronic liver inflammation, fibrosis, and ultimately, HCC.

Lung Cancer

Although lung cancer is not anatomically connected to the gut, the gut microbiome's role in modulating the immune system has implications for lung cancer patients. Recent research has shown that the gut microbiome can influence the efficacy of immunotherapy in lung cancer [15].

Mechanisms of Interaction

The treatment of cancer has witnessed remarkable advancements over the years, with a growing understanding of the intricate mechanisms involved in cancer progression and therapy. One area of significant interest is the interaction between the host and the tumor microenvironment. Several factors contribute to this interaction, including metabolites, immune system modulation, the gut microbiome, and their profound influence on cancer therapy outcomes. This article explores these mechanisms of interaction and their impact on cancer treatment, with a specific focus on metabolites, immune system modulation, the gut microbiome, and their relationship with chemotherapy and immunotherapy.

Metabolites and Their Impact

Metabolites are small molecules produced during various metabolic processes within the body, and they play a crucial role in cancer development, progression, and therapy. Metabolites can act as signaling molecules that influence the tumor microenvironment and the host's immune system. One well-studied class of metabolites is the oncometabolites, which are metabolites with the potential to promote cancer development. These oncometabolites include 2-hydroxyglutarate (2-HG), succinate, and fumarate, which are associated with specific genetic mutations in cancer [16]. For instance, mutations in isocitrate dehydrogenase (IDH) genes result in the accumulation of 2-HG, which has been shown to promote tumor growth by altering epigenetic regulation. The impact of such oncometabolites on cancer progression is well-documented, and targeting them has emerged as a potential therapeutic strategy [17].

On the other hand, metabolites derived from the microbiome have gained attention for their ability to affect cancer therapy outcomes. For example, the gut microbiome can metabolize dietary components such as flavonoids and fiber to produce short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate. These SCFAs have been shown to modulate immune responses and influence the response to cancer therapy. Butyrate, in particular, is known to exert anti-inflammatory and immune-enhancing effects that may contribute to improved therapeutic responses. Metabolites also have implications for chemotherapy and immunotherapy. The metabolism of drugs within the body can lead to the formation of active or inactive metabolites, affecting drug efficacy and toxicity. Understanding how individual variation in metabolite production and metabolism influences drug responses is an ongoing area of research that holds promise for optimizing cancer treatment strategies [18].

Immune System Modulation

The immune system plays a pivotal role in recognizing and eliminating cancer cells, and its modulation can significantly impact the outcome of cancer therapy. Immunotherapy, a promising approach to treating cancer, harnesses the power of the immune system to target and destroy cancer cells. Understanding the mechanisms of immune system modulation in the context of cancer therapy is crucial for improving treatment outcomes. Immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-CTLA-4 antibodies, have shown remarkable success in a variety of cancers. These therapies work by blocking inhibitory signals that cancer cells use to evade immune recognition (Fig. 2). However, response rates to ICIs can vary greatly among patients, and a better understanding of the factors that influence immune response modulation is needed [19].

Fig. 2.

Immune checkpoint blockade-based mechanism of the gut microbiome in cancer treatment

Several factors impact immune system modulation in the context of cancer therapy. One key determinant is the tumor microenvironment, which can be immunosuppressive due to factors like the accumulation of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). Modulating the tumor microenvironment to favor immune activation is a focus of ongoing research and therapeutic development [20].

Another significant factor in immune modulation is the gut microbiome. The gut microbiome has been shown to influence the effectiveness of immunotherapy. Specific bacterial species, such as Akkermansia muciniphila and Bifidobacterium, have been associated with improved responses to immunotherapy. The presence of these beneficial bacteria may enhance the immune system's ability to recognize and attack cancer cells. The use of antibiotics, which can alter the composition of the gut microbiome, has been associated with reduced responsiveness to immunotherapy. This highlights the importance of considering the gut microbiome in treatment decisions and potentially developing strategies to optimize the gut microbiome for immunotherapy efficacy. In addition to immunotherapy, immune system modulation can also influence chemotherapy outcomes (Fig. 3). Some chemotherapeutic agents, such as anthracyclines, can stimulate immune responses by promoting the release of damage-associated molecular patterns (DAMPs) and tumor-specific antigens. The interaction between chemotherapy and the immune system is complex, and a better understanding of this interplay is needed to optimize treatment strategies [21].

Fig. 3.

Mechanism of gut microbiome in cancer treatment by combined chemotherapy and immunotherapy techniques [21]

Gut Microbiome and Chemotherapy Response

The gut microbiome, composed of trillions of microorganisms, has a significant influence on various aspects of health, including its impact on the efficacy and toxicity of chemotherapy. This intricate relationship between the gut microbiome and chemotherapy response is an area of active research and is increasingly recognized as a crucial determinant of treatment outcomes. The gut microbiome can metabolize chemotherapeutic drugs, affecting their bioavailability and activity. For example, the microbiota can enzymatically convert prodrugs into their active forms or, conversely, inactivate drugs. This microbial metabolism can lead to variations in drug efficacy among individuals. Understanding the specific microbiota-driven metabolic pathways involved in drug metabolism is essential for optimizing treatment regimens. Moreover, the gut microbiome can influence the immune system's response to chemotherapy. Chemotherapy-induced changes in the gut microbiome can lead to the release of microbial-derived signals, which can stimulate the immune system. This immune activation can enhance the antitumor effects of chemotherapy. However, it can also contribute to inflammatory side effects and adverse events. Thus, a balanced modulation of the gut microbiome may be crucial in achieving the desired therapeutic outcome [22].

Importantly, the gut microbiome is not static but can be manipulated. Strategies such as probiotics, prebiotics, and fecal microbiota transplantation (FMT) are being explored to modify the gut microbiome to enhance chemotherapy response and reduce side effects. These interventions aim to restore or promote a microbiota composition that supports both drug metabolism and immune function [23].

In colorectal cancer, for example, the gut microbiome composition has been associated with the response to irinotecan-based chemotherapy. Patients with a higher abundance of specific bacterial strains, such as F. nucleatum, have been shown to have poorer responses to treatment. In contrast, a diverse and balanced gut microbiome may be more favorable for chemotherapy responsiveness [19].

Gut Microbiome and Immunotherapy

Immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to target and eliminate cancer cells. The gut microbiome has emerged as a key player in influencing the efficacy of immunotherapy, including checkpoint inhibitors and adoptive cell therapies. The intricate interactions between the gut microbiome and immunotherapy have important implications for personalized cancer treatment strategies. The interplay between the gut microbiome and immunotherapy involves intricate mechanisms that impact the systemic immune response. Commensal bacteria in the gut have been shown to influence the maturation and activation of immune cells, including T cells. These cells, when appropriately activated, play a crucial role in recognizing and attacking cancer cells. Furthermore, the gut microbiota can modulate the balance between pro-inflammatory and anti-inflammatory signals, affecting the overall immune milieu. Specific bacteria have been implicated in the activation of dendritic cells and the promotion of a pro-inflammatory environment that enhances the efficacy of immunotherapy.

A landmark study by Vetizou et al. demonstrated that the efficacy of anti-CTLA-4 immunotherapy was dependent on the presence of specific bacteria in the gut. Mice treated with antibiotics, which significantly altered their gut microbiota, exhibited diminished responses to the immunotherapy compared to mice with an intact microbiome. This research highlighted the critical role of the gut microbiota in mediating the anti-tumor effects of immunotherapy [24].

Several studies have identified distinct microbial signatures associated with differential responses to immunotherapy. The composition of the gut microbiota has been linked to response rates and overall survival in patients undergoing immune checkpoint blockade therapy. Notably, responders to immunotherapy often exhibit a higher abundance of specific bacterial taxa compared to non-responders. Research by Matson et al. found that patients with metastatic melanoma who responded positively to anti-PD-1 therapy had a higher abundance of certain bacteria, including Bifidobacterium longum and Faecalibacterium prausnitzii, in their gut microbiome. Conversely, non-responders had a distinct microbial profile characterized by a relative lack of these beneficial bacteria. This correlation suggests that the gut microbiome may serve as a biomarker for predicting patient response to immunotherapy [25].

Preclinical and Clinical Studies on Gut Microbiome in Cancer Treatment

The gut microbiome has emerged as a critical player in cancer treatment, with preclinical and clinical studies providing valuable insights into the complex interplay between the microbial communities residing in the gastrointestinal tract and cancer therapies. This article explores the findings from both animal studies and human clinical trials, highlighting key discoveries and acknowledging the limitations that researchers encounter in this rapidly evolving field. Preclinical studies utilizing animal models have been instrumental in unraveling the intricate mechanisms through which the gut microbiome influences cancer treatment outcomes. One landmark study by Viaud et al. delved into the impact of the gut microbiota on the anticancer immune effects of cyclophosphamide. The researchers discovered that specific bacteria, such as segmented filamentous bacteria, played a pivotal role in enhancing the therapeutic effects of cyclophosphamide. This finding underscored the potential of the gut microbiome to modulate the immune response, thereby influencing the efficacy of chemotherapy [10].

One groundbreaking clinical study led by Gopalakrishnan et al. focused on the relationship between the gut microbiome and the response to immune checkpoint inhibitors (ICIs) in patients with melanoma. The researchers found that patients with a favorable gut microbiome profile exhibited higher response rates and improved survival during anti-PD-1 immunotherapy. This study highlighted the potential of microbiome-based biomarkers in predicting immunotherapy outcomes [26].

Clinical trials have also explored interventions aimed at modulating the gut microbiome to enhance cancer treatment outcomes. Wang et al. investigated the impact of a probiotic mixture on the gut microbiota and immune response in colorectal cancer patients undergoing chemotherapy. The administration of probiotics was associated with favorable changes in the gut microbiome composition and enhanced anti-tumor immune responses, suggesting that manipulating the microbiome through probiotics holds promise as an adjuvant therapy in cancer treatment [27].

Human clinical trials represent a critical bridge between preclinical research and the application of gut microbiome knowledge to human health. These trials involve testing hypotheses and interventions related to the gut microbiome in real human subjects, offering direct insights into the impact of microbiota on health and disease. While the field of clinical trials involving the gut microbiome is still evolving, several notable findings have emerged [28].

Clinical trials have explored the use of probiotics and prebiotics in modifying the gut microbiota. Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits to the host. They have been studied for their potential to improve gut health, reduce gastrointestinal symptoms, and support the immune system. Prebiotics, on the other hand, are non-digestible food components that promote the growth of beneficial gut bacteria. Clinical trials have shown that both probiotics and prebiotics can influence the gut microbiota's composition and function, with implications for conditions like irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) [29]. Translating insights from animal studies to human applications, clinical trials have been pivotal in elucidating the role of the gut microbiome in cancer treatment (Fig. 4).

Fig. 4.

Gut microbiome in cancer treatment

Fecal Microbiota Transplantation (FMT) involves the transfer of fecal matter from a healthy donor to a recipient's colon to restore a balanced gut microbiome. This approach has gained significant attention for its remarkable success in treating recurrent Clostridioides difficile infection (CDI). Clinical trials have confirmed the efficacy of FMT in CDI and are now exploring its potential applications in other conditions, including inflammatory bowel diseases and metabolic disorders. Clinical trials have investigated the impact of dietary interventions on the gut microbiome. These studies have shown that changes in diet, such as adopting a high-fiber diet or a Mediterranean diet, can lead to shifts in the gut microbiota composition, with potential benefits for metabolic health and inflammation. The effects of diet on the gut microbiome are complex and often individualized, reflecting the diversity of human microbiota. Human clinical trials have provided valuable insights into the connections between the gut microbiome and various diseases. For example, studies have shown associations between gut dysbiosis (microbial imbalance) and conditions like obesity, diabetes, autoimmune diseases, and even mental health disorders. Understanding these associations can lead to the development of targeted interventions and therapies [30].

Gut Microbiome Modulation in Cancer Treatment

The human gut microbiome, a complex ecosystem of trillions of microorganisms, has been increasingly recognized as a critical player in maintaining health and influencing various disease states. Among the many diseases under investigation, cancer has garnered significant attention in recent years due to its devastating impact on global health. Research has illuminated the multifaceted role of the gut microbiome in cancer development and treatment.

Probiotics are live microorganisms that, when administered in adequate amounts, confer a health benefit to the host. Prebiotics are non-digestible compounds that selectively stimulate the growth and activity of beneficial gut bacteria. Both probiotics and prebiotics have emerged as potential tools in cancer treatment by modulating the gut microbiome [31]. Studies have shown that certain probiotics can enhance the immune response and exhibit antitumor effects. Prebiotics, on the other hand, can selectively promote the growth of beneficial gut bacteria. The increased presence of these beneficial bacteria can positively influence the gut microenvironment and, consequently, the host's overall health. Although direct evidence linking prebiotic consumption to cancer treatment is limited, their role in supporting gut health and immunity is well established [32].

While probiotics and prebiotics hold promise in cancer treatment, caution is necessary. The effects of probiotics and prebiotics can vary among individuals, and not all strains or compounds may be suitable for cancer patients. Further research is needed to determine the most effective strains and formulations, as well as optimal dosages for specific cancer types. A study by Sivan et al. demonstrated that specific bacterial species within the gut microbiome enhance the efficacy of immune checkpoint inhibitors in melanoma treatment. While the exact mechanisms are still being elucidated, it is hypothesized that probiotics may positively impact the tumor microenvironment and immune response [33].

Dietary interventions, including both the modification of dietary habits and the inclusion of specific dietary components, have been explored as a means to modulate the gut microbiome in the context of cancer treatment [34]. Several studies have highlighted the influence of diet on cancer risk and progression. Additionally, diets rich in plant-based foods, such as fruits, vegetables, and whole grains, are associated with a lower risk of various cancers. These foods provide phytonutrients, antioxidants, and other bioactive compounds that can support the body's natural defense mechanisms against cancer [35].

Conversely, diets high in red and processed meats have been linked to an increased risk of colorectal cancer. The gut microbiome can metabolize components of red meat, leading to the production of potentially carcinogenic compounds. Reducing the consumption of these meats may help mitigate this risk. Moreover, certain dietary components, such as polyphenols and omega-3 fatty acids, have demonstrated anticancer properties by modulating the gut microbiome. Polyphenols, found in foods like green tea, red wine, and berries, have been shown to promote the growth of beneficial bacteria and inhibit the proliferation of harmful bacteria. Omega-3 fatty acids, abundant in fatty fish, flaxseeds, and walnuts, can also influence the gut microbiome positively [36].

Personalized Medicine and Biomarkers in Cancer Treatment

Personalized medicine stands at the forefront of contemporary healthcare, promising a shift from generalized treatments to precision therapies tailored to individual characteristics. Central to this paradigm are biomarkers, providing insights into the unique biological signatures of patients. This essay investigates the intricate world of personalized medicine, with a special emphasis on the gut microbiome as a biomarker, its application in tailoring cancer treatments, and the ethical and regulatory dimensions that accompany this transformative approach. Biomarkers, defined as measurable indicators of biological processes or responses to treatment, are the linchpin of personalized medicine. They serve as diagnostic tools, enabling clinicians to identify individuals likely to benefit from specific treatments while minimizing adverse effects. Biomarkers encompass a spectrum of indicators, ranging from genetic and molecular signatures to physiological parameters. In the realm of personalized medicine, biomarkers offer a roadmap for individualized treatment plans. By analyzing these markers, clinicians gain valuable insights into the intricacies of a patient's health, enabling tailored interventions that optimize therapeutic outcomes.

Gut Microbiome as a Biomarker

The human gut microbiome, a complex community of microorganisms residing in the gastrointestinal tract, has emerged as a potential biomarker in the personalized medicine landscape. Research indicates that variations in the composition and diversity of the gut microbiome are associated with various health conditions, rendering it a promising candidate for personalized diagnostics. The composition of the gut microbiome has been intricately linked to overall health. Dysbiosis, or an imbalance in microbial communities, has been associated with conditions such as inflammatory bowel disease, obesity, and neurological disorders [37]. Analyzing the baseline composition of the gut microbiome offers valuable insights into an individual's predisposition to certain diseases. Recent studies have underscored the role of gut microbiome composition in predicting health outcomes [38]. The identification of specific microbial profiles associated with various health conditions paves the way for personalized interventions that target the root causes of diseases [39].

Beyond its role in health, the gut microbiome influences drug metabolism, potentially impacting the efficacy and safety of medications. Variations in microbial enzymes can affect the activation or inactivation of drugs, highlighting the gut microbiome's potential as a biomarker for predicting drug responses. The gut microbiome's influence on drug metabolism is a burgeoning area of research [40]. By understanding how individual microbial communities interact with medications, clinicians can tailor drug regimens to optimize therapeutic outcomes and minimize side effects [41].

One example of the gut microbiome serving as a biomarker in cancer is the association between specific microbial signatures and colorectal cancer. Certain gut bacteria, such as F. nucleatum, are more prevalent in colorectal cancer patients, suggesting a potential diagnostic and prognostic biomarker [8]. Identifying such microbial signatures can aid in the early detection and risk assessment of cancer.

Tailoring Microbiome-Based Cancer Treatment

Cancer, characterized by its heterogeneity, presents a unique challenge for personalized treatment. Recent advancements suggest that the gut microbiome plays a crucial role in modulating responses to cancer therapies, providing a novel avenue for tailoring treatments to individual patients. Immunotherapy, a groundbreaking approach to cancer treatment, leverages the body's immune system to target and eliminate cancer cells. Research indicates that the gut microbiome influences the response to immunotherapy, with specific microbial communities enhancing or inhibiting treatment outcomes. Understanding the interplay between the gut microbiome and immunotherapy response is a frontier in cancer research [42]. Tailoring immunotherapy based on an individual's gut microbial profile holds promise for optimizing treatment efficacy and improving patient outcomes [43].

Chemotherapy, a cornerstone of cancer treatment, often entails severe side effects. The gut microbiome has been implicated in modulating the toxicity of chemotherapy drugs, offering a potential avenue for personalized chemotherapy regimens that mitigate adverse effects. Research on the relationship between the gut microbiome and chemotherapy toxicity is evolving [44]. By identifying microbial signatures associated with drug toxicity, clinicians can tailor chemotherapy regimens to individual patients, enhancing treatment tolerability and efficacy [45].

Ethical and Regulatory Considerations

While personalized medicine holds immense potential, it introduces complex ethical and regulatory challenges that necessitate careful consideration to ensure responsible and equitable implementation. The collection and analysis of extensive personal health data demand robust mechanisms for informed consent and data privacy. Ensuring that patients are fully informed about the potential risks and benefits of participating in personalized medicine initiatives is crucial, as is safeguarding their privacy rights. Informed consent in personalized medicine requires careful consideration of the unique ethical implications associated with genetic and personal health data [46]. Striking a balance between data sharing for scientific advancement and protecting individual privacy rights is paramount [43]. Addressing disparities in access to personalized medicine is an ethical imperative [47].

Policies and interventions that prioritize inclusivity and reduce barriers to access are essential for realizing the full potential of personalized medicine for all patients [48]. Transparency and accountability are cornerstones of ethical personalized medicine practices. Establishing frameworks for responsible research conduct, data use, and communication of results is essential in gaining and maintaining public trust [49]. The rapid evolution of personalized medicine requires adaptable and comprehensive regulatory frameworks. Regulatory bodies must balance the need for fostering innovation with ensuring the safety and efficacy of personalized treatments. Collaborative efforts between researchers, clinicians, and regulators are essential for developing and updating these frameworks in tandem with advancements in the field. The development of regulatory frameworks is an ongoing process that requires collaboration across disciplines [39]. Flexibility, responsiveness to emerging technologies, and consideration of ethical principles are crucial in creating a regulatory environment that promotes the responsible advancement of personalized medicine [50].

Clinical Applications of Gut Microbiome in Cancer Treatment

The human gut microbiome is a dynamic ecosystem composed of bacteria, viruses, fungi, and other microorganisms. This complex microbial community exerts a profound influence on host physiology and health. Research has shown that the gut microbiome has significant implications for cancer development, progression, and treatment. By manipulating the gut microbiome, clinicians can potentially enhance the efficacy of cancer therapies and reduce treatment-related side effects [51].

The gut microbiome, a diverse community of bacteria, viruses, fungi, and other microorganisms, has emerged as a significant player in cancer research. Numerous studies have shown that alterations in the gut microbiome composition can affect cancer susceptibility, response to therapy, and even cancer initiation. While the field of microbiome-cancer interactions is still evolving, this article delves into the current understanding of how the gut microbiome impacts various cancer types. The gut microbiome also plays a pivotal role in modulating the immune system's response to cancer. Microbial metabolites, such as SCFAs, produced by commensal bacteria, can enhance the anti-tumor immune response [52]. Additionally, the gut microbiome influences the efficacy of immunotherapy in various cancer types. Patients with a diverse and balanced gut microbiome composition tend to respond better to immune checkpoint inhibitors [42]. While colorectal cancer has been a primary focus, the gut microbiome also influences other cancer types, including breast cancer, pancreatic cancer, and liver cancer. Distinct microbial signatures have been identified in these diseases, suggesting that the gut microbiome may contribute to cancer development through various mechanisms, including inflammation, immune modulation, and metabolic alterations [13, 24].

Understanding the link between the gut microbiome and cancer has opened avenues for potential therapeutic interventions. Strategies like FMT and probiotics are being explored to modify the gut microbiome composition and enhance cancer treatment outcomes [53]. Furthermore, dietary interventions, such as prebiotics and dietary fiber, can promote a more favorable gut microbiome and reduce cancer risk [54].

Colorectal Cancer

Colorectal cancer is one of the most well-studied cancer types in the context of the gut microbiome. Research has highlighted specific bacterial species, such as F. nucleatum and Bacteroides fragilis, which are associated with an increased risk of CRC [8, 9]. These bacteria can promote inflammation and DNA damage, contributing to carcinogenesis. Conversely, some gut microbes, like certain strains of E. coli and Clostridium, can exert anti-tumor effects by producing metabolites that inhibit cancer cell growth [10, 11].

A substantial body of evidence has shown that alterations in the gut microbiome composition are associated with an increased risk of CRC. Furthermore, specific bacterial species and microbial metabolites have been linked to CRC pathogenesis. One key observation is the link between F. nucleatum and CRC. The F. nucleatum, a common gut bacterium, has been found in elevated levels in CRC patients. It is believed to promote inflammation and tumor progression. Several studies have demonstrated a correlation between F. nucleatum abundance and poor prognosis in CRC patients. This information can guide clinicians in evaluating patient prognosis and planning treatment strategies. Moreover, the gut microbiome can influence the efficacy and toxicity of CRC treatment. Chemotherapy drugs, such as 5-fluorouracil (5-FU), are commonly used in CRC treatment. Recent studies have shown that the gut microbiome can metabolize 5-FU, affecting its bioavailability and efficacy. By modulating the gut microbiome, clinicians can potentially optimize the therapeutic outcomes of CRC patients.

Breast Cancer

Breast cancer is another prevalent cancer type, and while it primarily affects the mammary tissue, the gut microbiome has been found to influence its development and response to treatment. Research has demonstrated that the gut microbiome can influence estrogen metabolism, which is relevant because estrogen exposure is a known risk factor for breast cancer. A study published by Fuhrman et al. found that the gut microbiome can impact the bioavailability of estrogens. Some gut bacteria are capable of metabolizing estrogen precursors, potentially increasing estrogen levels in the body. Elevated estrogen levels have been linked to an increased risk of breast cancer development. Therefore, understanding the composition and functionality of the gut microbiome in breast cancer patients can provide valuable insights for clinicians in assessing risk and designing personalized prevention and treatment strategies. Additionally, the gut microbiome can play a role in chemotherapy-related side effects in breast cancer patients. Chemotherapy often disrupts the gut microbiome, leading to gastrointestinal issues and increased susceptibility to infections. By carefully managing and restoring the gut microbiome, clinicians can potentially reduce these side effects and improve the overall quality of life for breast cancer patients during treatment [55].

Melanoma

Melanoma is a type of skin cancer that arises from melanocytes, the pigment-producing cells in the skin. While the gut microbiome is not directly related to melanoma development, it can have indirect effects on the immune system's response to cancer. Recent research has highlighted the connection between the gut microbiome and the efficacy of immunotherapy in melanoma treatment. Immunotherapy, particularly immune checkpoint inhibitors, has revolutionized the treatment of various cancer types, including melanoma. However, not all patients respond to immunotherapy, and treatment outcomes can vary significantly. The gut microbiome appears to be a crucial factor influencing the response to immunotherapy. Several studies have identified specific gut bacteria associated with improved response to immunotherapy in melanoma patients [56]. A study published by Gopalakrishnan et al. found that patients who responded well to anti-PD-1 immunotherapy had a higher abundance of specific bacterial species, such as B. longum and A. muciniphila, in their gut microbiota. Understanding these associations can help clinicians select the most appropriate treatment strategies for melanoma patients, increasing their chances of success [42].

Miscellaneous Cancer Types

Prostate Cancer

A study published by Ma et al. suggested a link between the gut microbiome and prostate cancer. The researchers found that certain gut bacteria could influence the expression of genes related to prostate cancer development [57]. Further research is needed to elucidate the precise mechanisms and clinical applications [58, 59].

Lung Cancer

The relationship between the lung and gut microbiome is an emerging area of research [60, 61]. Jin et al. demonstrated that changes in the gut microbiome could affect lung tumor growth in mice. This opens avenues for investigating the role of the gut microbiome in lung cancer and potential therapeutic strategies [62].

Pancreatic Cancer

Research into the gut microbiome's impact on pancreatic cancer is also underway [63, 64]. A study by Riquelme et al. highlighted differences in the gut microbiome of pancreatic cancer patients compared to healthy individuals. This research may lead to novel diagnostic and treatment approaches for pancreatic cancer [65].

Bladder Cancer

A study identified differences in the gut microbiome composition of bladder cancer patients [66]. While the clinical applications in bladder cancer are still emerging, this research may pave the way for personalized treatment strategies [57, 59].

Some studies related to the clinical application of gut microbiome in treatment of different cancers have been represented in Table 1.

Table 1.

Clinical applications of gut microbiome in treatment of different cancers

S. No	Study Title	NCT Number	Type of cancer	Interventions	Status	References
1	The gut microbiome and immune checkpoint inhibitor therapy in solid tumors	NCT05037825	Triple-negative breast cancer, Malignant melanoma, Non-small-cell lung carcinoma (NSCLC), Renal cell carcinoma	Immune checkpoint inhibitor	Recruiting	[67]
2	A study of the gut microbiome in hormone receptor-positive HER2-negative breast cancer treated with CDK4/6 inhibitors	NCT06171360	Breast cancer	CDK4/6 inhibitors	Recruiting	[68]
3	Role of the gut microbiome in the outcome of diffuse large B-Cell lymphoma patients treated with CAR-T cell therapy	NCT05725720	Diffuse large B cell lymphoma	Gut microbiome analysis	Recruiting	[69]
4	Melanoma checkpoint and gut microbiome alteration with microbiome intervention	NCT03817125	Metastatic melanoma	Nivolumab	Completed	[70]
5	Analysis of gut microbiota in patients with brain metastasis of non-small cell lung cancer treated by Pembrolizumab combined with chemotherapy	NCT04333004	Non-small-cell lung carcinoma (NSCLC)	Pembrolizumab combined with chemotherapy	Unknown	[71]
6	The gut microbiome and Sorafenib maintenance therapy in FLT3-ITD positive AML after Allo-HSCT	NCT05596968	Acute myeloid leukemia	Sorafenib	Recruiting	[72]
7	The role of the tumor molecular profile (CMS), UGT1A1 genotype and beta-glucuronidase activity of the intestinal microbiota for treatment efficiency, toxicity, survival and quality of life in patients with metastatic or unresectable colorectal cancer during Irinotecan-based systemic treatment	NCT05655780	Colorectal neoplasms	Irinotecan	Recruiting	[73]
8	Gut microbiome in fecal samples from patients with metastatic cancer undergoing chemotherapy or immunotherapy	NCT02960282	Colorectal cancer	Laboratory biomarker analysis	Terminated	[74]
9	Associations between chemotherapy-induced nausea in patients with genitourinary cancer and changes in gut microbiome	NCT05819827	Prostate cancer, Bladder cancer, Testicular cancer	Blood and Tissue	Recruiting	[75]
10	Study to detect changes in urinary and gut microbiome during androgen deprivation therapy and radiation therapy in patients with prostate cancer	NCT04775355	Prostate cancer	Biospecimen collection	Recruiting	[76]
11	Gut microbiome and its immune modulation in locally advanced rectal cancer	NCT05079503	Locally advanced rectal cancer	GEN-001	Unknown	[77]
12	Therapeutic outcomes related to gut microbiome in glioblastoma (GBM) patients receiving chemo-radiation (THERABIOME-GBM)	NCT05326334	Glioblastoma	–	Recruiting	[78]
13	FMT combined with immune checkpoint inhibitor and TKI in the treatment of CRC patients with advanced stage	NCT05279677	Malignant colorectal neoplasms	Fecal microbiota transplantation (FMT) plus Fruquintinib and Sintilimab	Unknown	[79]
14	Post-Ibrutinib colitis and intestinal microbiota	NCT03569137	Gastrointestinal microbiome	–	Unknown	[80]
15	BioForte technology for in silico identification of candidates for a new microbiome-based therapeutics and diagnostics	NCT04136470	Melanoma, Non-small-cell lung carcinoma (NSCLC)	Collection of stool, blood and biopsy	Unknown	[81]

Conclusion and Future Perspectives

The gut microbiome has emerged as a significant player in the complex landscape of cancer. Its influence on cancer development, progression, and response to therapy is multifaceted, involving mechanisms such as inflammation, metabolite production, and immune system modulation. Moreover, the gut microbiome's role extends beyond a single cancer type, with unique microbial signatures associated with various malignancies. The growing understanding of the gut microbiome's involvement in cancer holds promise for the development of innovative approaches for cancer prevention and treatment, offering new avenues for research and therapeutic strategies.

In conclusion, preclinical studies in animals and human clinical trials have significantly advanced our knowledge of the gut microbiome's role in health and disease. These studies have provided insights into the influence of probiotics, prebiotics, FMT, diet, and microbiome-disease associations. However, many challenges and limitations remain in translating this research into practical clinical applications. The gut microbiome is a dynamic and complex ecosystem that holds great promise for personalized medicine, but ongoing research is essential to unlock its full potential. The gut microbiome's role in cancer is a burgeoning field of research with significant implications for cancer prevention and treatment. By unraveling the complex interplay between the gut microbiome and cancer, we can potentially develop innovative strategies to manipulate the microbiome to our advantage. This evolving area of science promises new insights and therapeutic options for cancer patients in the future.

Funding

Not applicable.

Declarations

Conflict of interest

The authors declare no conflict of interest.